A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

作者：Williams Casey B; McMahon Caitlin; Ali Siraj M; Abramovitz Mark; Williams Kirstin A; Klein Jessica; McKean Heidi; Yelensky Roman; George Thomas J Jr; Elvin Julia A; Soman Salil; Lipson Doron; Chmielecki Juliann; Morosini Deborah; Miller Vincent A; Stephens Philip J; Ross Jeffrey S; Leyland Jones Brian^*

来源：OncoTargets and Therapy, 2015, 8: 3561-3564.

DOI：10.2147/OTT.S90766

• oxaliplatin
• colorectal adenocarcinoma
• combination targeted therapy
• BRAF mutations

The subset of metastatic colorectal adenocarcinomas that harbor BRAF V600E mutations are aggressive tumors with significantly shortened survival and limited treatment options. Here we present a colorectal cancer patient whose disease progressed through standard chemotherapy and who developed liver metastasis. Comprehensive genomic profiling (FoundationOne (R)) identified a BRAF V600E mutation in the liver lesion, as well as other genomic alterations consistent with colorectal cancers. Combination therapy of dabrafenib and trametinib with standard cytotoxic chemotherapy resulted in a durable major ongoing response for the patient. This report illustrates the utility of comprehensive genomic profiling with personalized targeted therapy for aggressive metastatic colorectal adenocarcinomas.

• 出版日期2015